Recent studies have reported that elevated HM13 expression correlates with poor prognosis in lung cancer, hepatocellular carcinoma, breast cancer, and glioblastoma patients (Wei et al. 2017; Zhang et al. 2022; Zhou et al. 2021; Yang et al. 2022). Here, HM13 is linked to breast carcinoma.